Perimeter Solutions, Inc.

DB:A40PUQ Stock Report

Market Cap: €1.8b

Perimeter Solutions Valuation

Is A40PUQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A40PUQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A40PUQ (€12.2) is trading below our estimate of fair value (€269.57)

Significantly Below Fair Value: A40PUQ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A40PUQ?

Key metric: As A40PUQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A40PUQ. This is calculated by dividing A40PUQ's market cap by their current revenue.
What is A40PUQ's PS Ratio?
PS Ratio3.6x
SalesUS$534.19m
Market CapUS$1.92b

Price to Sales Ratio vs Peers

How does A40PUQ's PS Ratio compare to its peers?

The above table shows the PS ratio for A40PUQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
WCH Wacker Chemie
0.6x5.2%€3.5b
ACT AlzChem Group
1.1x7.5%€606.5m
2NF Syensqo
1.1x4.2%€7.5b
EVK Evonik Industries
0.5x2.2%€8.2b
A40PUQ Perimeter Solutions
3.6x-2.7%€1.9b

Price-To-Sales vs Peers: A40PUQ is expensive based on its Price-To-Sales Ratio (3.6x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does A40PUQ's PS Ratio compare vs other companies in the DE Chemicals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
2HRA H&R GmbH KGaA
0.1x3.0%US$132.56m
NSAK OTI Greentech
0.03xn/aUS$594.62k
B7Y Byotrol
0.04xn/aUS$246.97k
No more companies available in this PS range
A40PUQ 3.6xIndustry Avg. 1.0xNo. of Companies4PS00.40.81.21.62+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A40PUQ is expensive based on its Price-To-Sales Ratio (3.6x) compared to the European Chemicals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is A40PUQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A40PUQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.6x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: A40PUQ is expensive based on its Price-To-Sales Ratio (3.6x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A40PUQ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€12.20
€15.15
+24.2%
12.5%€17.05€13.26n/a2
Nov ’25€12.30
€14.31
+16.4%
16.1%€16.62€12.01n/a2
Oct ’25€12.10
€13.03
+7.7%
24.1%€16.17€9.88n/a2
Sep ’25€10.50
€11.34
+8.0%
12.0%€12.70€9.98n/a2
Aug ’25€9.80
€9.59
-2.1%
15.7%€11.10€8.09n/a2
Jul ’25€6.95
€9.62
+38.4%
15.7%€11.12€8.11n/a2
Jun ’25€6.90
€9.62
+39.4%
15.7%€11.12€8.11n/a2
May ’25€6.50
€9.40
+44.5%
20.0%€11.27€7.52n/a2
Apr ’25€6.20
€7.39
+19.1%
12.5%€8.31€6.46n/a2
Mar ’25€5.75
€7.15
+24.3%
16.1%€8.30€5.99n/a2
Feb ’25€4.52
€6.21
+37.4%
33.3%€8.28€4.14n/a2
Jan ’25€4.06
€6.68
+64.6%
37.9%€9.22€4.15n/a2
Dec ’24€4.00
€6.68
+67.1%
37.9%€9.22€4.15n/a2
Nov ’24€2.64
€6.74
+155.2%
40.4%€9.46€4.02€12.302
Oct ’24€4.24
€8.63
+103.6%
26.3%€10.90€6.36€12.102
Sep ’24€5.45
€8.63
+58.4%
26.3%€10.90€6.36€10.502
Aug ’24€5.05
€8.63
+70.9%
26.3%€10.90€6.36€9.802
Jul ’24€5.60
€10.11
+80.6%
9.1%€11.03€9.19€6.952
Jun ’24€5.20
€10.11
+94.5%
9.1%€11.03€9.19€6.902
May ’24€6.50
€10.48
+61.3%
4.3%€10.94€10.03€6.502
Apr ’24€7.20
€12.32
+71.1%
7.7%€13.27€11.37€6.202
Mar ’24€8.15
€12.19
+49.6%
7.7%€13.13€11.25€5.752
Feb ’24€8.35
€12.08
+44.7%
7.7%€13.01€11.15€4.522
Jan ’24€8.20
€12.34
+50.5%
7.7%€13.29€11.39€4.062
Dec ’23€10.10
€12.97
+28.4%
7.7%€13.97€11.97€4.002
Nov ’23€7.55
€13.26
+75.7%
7.7%€14.28€12.24€2.642

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Stanmore Resources

AU$2.8b

Engages in the exploration, development, production, and sale of metallurgical coal in Australia.

S0D

AU$1.91

7D

4.9%

1Y

-15.5%

Tokuyama

JP¥196.7b

Produces and sells various chemical products in Japan.

TBT

JP¥16.60

7D

5.7%

1Y

14.5%

Arkema

€5.7b

Manufactures and sells specialty chemicals and advanced materials worldwide.

V1S

€74.55

7D

-4.4%

1Y

-19.9%